Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94


Application of a human multidrug transporter (ABCG2) variant as selectable marker in gene transfer to progenitor cells.

Ujhelly O, Ozvegy C, Várady G, Cervenak J, Homolya L, Grez M, Scheffer G, Roos D, Bates SE, Váradi A, Sarkadi B, Német K.

Hum Gene Ther. 2003 Mar 1;14(4):403-12. No abstract available.


Cloning and functional analysis of the rhesus macaque ABCG2 gene. Forced expression confers an SP phenotype among hematopoietic stem cell progeny in vivo.

Ueda T, Brenner S, Malech HL, Langemeijer SM, Perl S, Kirby M, Phang OA, Krouse AE, Donahue RE, Kang EM, Tisdale JF.

J Biol Chem. 2005 Jan 14;280(2):991-8. Epub 2004 Oct 30.


The multidrug resistance transporter ABCG2 (breast cancer resistance protein 1) effluxes Hoechst 33342 and is overexpressed in hematopoietic stem cells.

Kim M, Turnquist H, Jackson J, Sgagias M, Yan Y, Gong M, Dean M, Sharp JG, Cowan K.

Clin Cancer Res. 2002 Jan;8(1):22-8.


Constitutive expression of the ATP-binding cassette transporter ABCG2 enhances the growth potential of early human hematopoietic progenitors.

Ahmed F, Arseni N, Glimm H, Hiddemann W, Buske C, Feuring-Buske M.

Stem Cells. 2008 Mar;26(3):810-8. Epub 2007 Nov 29.


Antibody-directed lentiviral gene transduction in early immature hematopoietic progenitor cells.

Zhang X, Roth MJ.

J Gene Med. 2010 Dec;12(12):945-55. doi: 10.1002/jgm.1518.


Correction of respiratory burst activity in X-linked chronic granulomatous cells to therapeutically relevant levels after gene transfer into bone marrow CD34+ cells.

Becker S, Wasser S, Hauses M, Hossle JP, Ott MG, Dinauer MC, Ganser A, Hoelzer D, Seger R, Grez M.

Hum Gene Ther. 1998 Jul 20;9(11):1561-70.


Drug-selected co-expression of P-glycoprotein and gp91 in vivo from an MDR1-bicistronic retrovirus vector Ha-MDR-IRES-gp91.

Sugimoto Y, Tsukahara S, Sato S, Suzuki M, Nunoi H, Malech HL, Gottesman MM, Tsuruo T.

J Gene Med. 2003 May;5(5):366-76.


Retroviral gene therapy for X-linked chronic granulomatous disease: results from phase I/II trial.

Kang HJ, Bartholomae CC, Paruzynski A, Arens A, Kim S, Yu SS, Hong Y, Joo CW, Yoon NK, Rhim JW, Kim JG, Von Kalle C, Schmidt M, Kim S, Ahn HS.

Mol Ther. 2011 Nov;19(11):2092-101. doi: 10.1038/mt.2011.166. Epub 2011 Aug 30.


Concentrated RD114-pseudotyped MFGS-gp91phox vector achieves high levels of functional correction of the chronic granulomatous disease oxidase defect in NOD/SCID/beta -microglobulin-/- repopulating mobilized human peripheral blood CD34+ cells.

Brenner S, Whiting-Theobald NL, Linton GF, Holmes KL, Anderson-Cohen M, Kelly PF, Vanin EF, Pilon AM, Bodine DM, Horwitz ME, Malech HL.

Blood. 2003 Oct 15;102(8):2789-97. Epub 2003 Jun 26.


Human miR223 promoter as a novel myelo-specific promoter for chronic granulomatous disease gene therapy.

Brendel C, Hänseler W, Wohlgensinger V, Bianchi M, Tokmak S, Chen-Wichmann L, Kuzmenko E, Cesarovic N, Nicholls F, Reichenbach J, Seger R, Grez M, Siler U.

Hum Gene Ther Methods. 2013 Jun;24(3):151-9. doi: 10.1089/hgtb.2012.157. Epub 2013 May 2.


Prolonged production of NADPH oxidase-corrected granulocytes after gene therapy of chronic granulomatous disease.

Malech HL, Maples PB, Whiting-Theobald N, Linton GF, Sekhsaria S, Vowells SJ, Li F, Miller JA, DeCarlo E, Holland SM, Leitman SF, Carter CS, Butz RE, Read EJ, Fleisher TA, Schneiderman RD, Van Epps DE, Spratt SK, Maack CA, Rokovich JA, Cohen LK, Gallin JI.

Proc Natl Acad Sci U S A. 1997 Oct 28;94(22):12133-8.


The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype.

Zhou S, Schuetz JD, Bunting KD, Colapietro AM, Sampath J, Morris JJ, Lagutina I, Grosveld GC, Osawa M, Nakauchi H, Sorrentino BP.

Nat Med. 2001 Sep;7(9):1028-34.


Lentivirus-mediated gene transfer of gp91phox corrects chronic granulomatous disease (CGD) phenotype in human X-CGD cells.

Saulnier SO, Steinhoff D, Dinauer MC, Zufferey R, Trono D, Seger RA, Hossle JP.

J Gene Med. 2000 Sep-Oct;2(5):317-25.


Gene therapy of chronic granulomatous disease (CGD) by gene transfer into hematopoietic stem cells.

Zentilin L, Tafuro S, Serra C, Falaschi A, Giacca M.

Ann Ist Super Sanita. 1998;34(4):447-55.


Transgene optimization significantly improves SIN vector titers, gp91phox expression and reconstitution of superoxide production in X-CGD cells.

Moreno-Carranza B, Gentsch M, Stein S, Schambach A, Santilli G, Rudolf E, Ryser MF, Haria S, Thrasher AJ, Baum C, Brenner S, Grez M.

Gene Ther. 2009 Jan;16(1):111-8. doi: 10.1038/gt.2008.143. Epub 2008 Sep 11.


Supplemental Content

Support Center